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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER2047Omega-3 Fatty Acids and Cardiovascular DiseaseDariush Mozaffarian, Jason H. Y. Wu
Mozaffarian and Wu review the putative cardiovascular benefits of n-3 polyunsaturated fatty
acid (PUFA) consumption. n-3 PUFA consumption lowers plasma triglycerides, resting heart
rate, and blood pressure; it may also improve myocardial filling, lower inflammation, and
improve vascular function. In prospective observational studies and adequately powered trials,
benefits of n-3 PUFA are most consistent for coronary heart disease mortality and sudden
cardiac death. The evidence for beneficial effects on other cardiovascular outcomes is reviewed.
National and international guidelines have converged on consistent recommendations for
the consumption of at least 250 mg/day of long-chain n-3 PUFA or at least 2 servings/week
of oily fish.CLINICAL RESEARCH CORONARY ARTERY DISEASE2068The Anti-Oxidative Capacity of HDL Is Reduced in ACS PatientsParin J. Patel, Amit V. Khera, Kashif Jafri, Robert L. Wilensky, Daniel J. Rader
Patel and colleagues studied the anti-inflammatory properties of high-density lipoprotein
(HDL) in subjects with acute coronary syndrome (ACS) and stable coronary artery disease
(CAD) compared with control subjects. Previous research has shown that HDL has anti-
inflammatory properties that can be measured by the ability of HDL to limit oxidation of
low-density lipoprotein and are termed the high-density lipoprotein inflammatory index
(HII). HII was measured in 193 patients undergoing angiography and healthy controls.
Subjects who presented with an acute coronary syndrome (ACS) had higher HII (less anti-
oxidative capacity) compared with controls or those with chronic CAD. Whether the reduced
anti-oxidative capacity of HDL causes or is the result of an ACS will require further study.(continued on page A-26)
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2076Reynolds Risk Score Is Superior to Framingham Risk Score
for Predicting Progression of CACAndrew P. DeFilippis, Michael J. Blaha, Chiadi E. Ndumele, Matthew J. Budoff, Donald M. Lloyd-Jones,
Robyn L. McClelland, Susan G. Lakoski, Mary Cushman, Nathan D. Wong, Roger S. Blumenthal,
Joao Lima, Khurram Nasir
DeFilippis and colleagues compared the Framingham Risk Score (FRS) and the Reynolds
Risk Score (RRS) for predicting the presence and progression of coronary artery calcium
(CAC) using subjects from the MESA (Multi-Ethnic Study of Atherosclerosis). In the 50%
of subjects with no baseline CAC, 18% developed CAC on subsequent imaging. Both the
FRS and RRS were significantly predictive of incident CAC and CAC progression, but the
RRS was more often accurate. These results show that both the RRS and FRS predict onset
and progression of subclinical atherosclerosis, but the RRS appears to be superior.HEART FAILURE
2084Renin-Angiotensin Aldosterone System Blockade May
Improve Mortality in Patients With Moderate to Severe ARDouglas H. J. Elder, Li Wei, Benjamin R. Szwejkowski, Renata Libianto, Adnan Nadir,
Maheshwar Pauriah, Sushma Rekhraj, Tiong K. Lim, Jacob George, Alex Doney, Stuart D. Pringle,
Anna-Maria Choy, Allan D. Struthers, Chim C. Lang
Elder and colleagues investigated the effect of renin-angiotensin system (RAS) blockade in
patients with aortic regurgitation (AR) using a retrospective query of a large echocardiography
database and a medication dispensing program. Over 2,000 subjects with moderate to severe
AR were studied, with a median follow-up of 4.4 years. One-third of patients received
angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy, and these
subjects were approximately one-half as likely to die during follow-up, despite more
cardiovascular risk factors at baseline. While a prospective randomized trial is needed, these
results suggest that RAS inhibition in patients with moderate to severe AR may greatly
improve outcomes.
Editorial Comment: Linda Gillam, p. 2092(continued on page A-28)
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2095Impaired Renal Endocrine Response to Acute Volume Expansion
in Pre-Clinical Systolic and Diastolic DysfunctionPaul M. McKie, John A. Schirger, Lisa C. Costello-Boerrigter, Sherry L. Benike, Lynn K. Harstad,
Kent R. Bailey, David O. Hodge, Margaret M. Redfield, Robert D. Simari, John C. Burnett, Jr,
Horng H. Chen
McKie and colleagues hypothesized that patients with pre-clinical systolic dysfunction (PSD)
or pre-clinical diastolic dysfunction (PDD) would have an impaired response to acute volume
expansion (VE). PSD was defined as left ventricular ejection fraction (EF) 40% without
heart failure (HF) symptoms. PDD was defined as EF 50%, moderate to severe diastolic
dysfunction, and no HF symptoms. In healthy controls, urinary cyclic guanosine monophosphate
(cGMP) and natriuresis increased following VE with normal saline infusion. In PSD and
PDD subjects, there was a paradoxical decrease in urinary cGMP and attenuated natriuresis.
Impaired activation of urinary cGMP and reduced natriuresis may contribute to volume
overload and the progression of HF symptoms in patients with PSD or PDD.Editorial Comment: Wilfried Mullens, W. H. Wilson Tang, p. 2104HEART RHYTHM DISORDERS
2106Mechanical Stretch of Atrial Myocytes Predisposes
to Repolarization Alternans and May Increase Susceptibility to AFChia-Ti Tsai, Fu-Tien Chiang, Chuen-Den Tseng, Chih-Chieh Yu, Yi-Chih Wang, Ling-Ping Lai,
Juey-Jen Hwang, Jiunn-Lee Lin
Discordant repolarization alternans, characterized by simultaneous prolongation and
shortening of action potential duration in different regions, is capable of generating ventricular
fibrillation and may predispose to atrial fibrillation (AF). Tsai and colleagues investigated
whether mechanical stretch could produce alterations in the electrical properties of atrial
myocytes. Mechanical stretch significantly decreased the thresholds for alternans via decreased
expression of sarcoplasmic reticulum ATPase 2 and, thus, slower calcium reuptake kinetics.
These results might explain the increased susceptibility to AF in conditions of atrial stretch,
such as valvular heart disease, heart failure, and hypertension.
Editorial Comment: Jérôme Kalifa, Masatoshi Yamazaki, p. 2116(continued on page A-32)
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2118Reduced Collagen Deposition in Infarcted Myocardium
Facilitates Stem Cell EngraftmentBo Dai, Wei Huang, Meifeng Xu, Ronald W. Millard, Mei Hua Gao, H. Kirk Hammond,
Donald R. Menick, Muhammad Ashraf, Yigang Wang
Dai and colleagues studied the utility of a peritoneal patch seeded and cultured with induced
pluripotent stem cell-derived cardiomyocytes, endothelial cells, and mouse embryonic
fibroblasts to stimulate functional recovery after a myocardial infarction (MI). The patch was
affixed to the epicardial surface of the infarcted area 7 days after an MI in a mouse model and
showed promise. This patch was then tested in mice bred to overexpress adenylyl cyclase VI
(AC6). AC6 mice showed significantly higher cell engraftment than wild-type (WT) mice,
with improved left ventricular function. These results suggest 2 complementary techniques to
reduce scar tissue formation and stimulate functional recovery after MI.Editorial Comment: Marc S. Penn, Horst A. von Recum, p. 2128EXPEDITED PUBLICATIONS EXPEDITED PUBLICATIONS
2130Long-Term Outcomes After Transcatheter Aortic Valve Implantation
in High-Risk Patients With Severe Aortic StenosisNeil E. Moat, Peter Ludman, Mark A. de Belder, Ben Bridgewater, Andrew D. Cunningham,
Christopher P. Young, Martyn Thomas, Jan Kovac, Tom Spyt, Philip A. MacCarthy, Olaf Wendler,
David Hildick-Smith, Simon W. Davies, Uday Trivedi, Daniel J. Blackman, Richard D. Levy,
Stephen J. D. Brecker, Andreas Baumbach, Tim Daniel, Huon Gray, Michael J. Mullen
Although a substantial body of data exists for the early clinical outcomes after transcatheter
aortic valve implantation (TAVI), there is less data on outcomes beyond 1 year. Moat and
colleagues reviewed data from the United Kingdom TAVI Registry, which collects data on
every TAVI procedure performed within the United Kingdom. There were 877 patients who
were enrolled prior to December 2009. Survival at 30 days was 93%, and it was 79% and 74%
at 1 and 2 years, respectively. There was a marked attrition in survival between 30 days and 1
year. In a multivariate model, left ventricular dysfunction, aortic regurgitation, and chronic
obstructive pulmonary disease were independent predictors of mortality. Midterm to long-
term survival after TAVI is acceptable in this high-risk patient population, although a
substantial proportion of patients died within the first year.Editorial Comment: Alec Vahanian, Dominique Himbert, Bernard Iung, p. 2139
